Corbus Pharmaceuticals(US:CRBP)2025-11-12 13:14Financial Performance - Corbus Pharmaceuticals reported a net loss of approximately $23.3 million, or $1.90 per share, for Q3 2025, compared to a net loss of $13.8 million, or $1.15 per share, in Q3 2024[11]. - The company reported a comprehensive loss of $23.3 million for Q3 2025, compared to a comprehensive loss of $13.2 million in Q3 2024[23]. - As of September 30, 2025, total assets were $109.5 million, down from $155.9 million at the end of 2024, primarily due to cash and investment reductions[25]. - The weighted average number of common shares outstanding increased to 12,307,298 in Q3 2025 from 12,014,700 in Q3 2024[23]. Operating Expenses - Operating expenses increased by $8.9 million to approximately $24.4 million in Q3 2025, primarily due to higher clinical development expenses[12]. Funding and Cash Position - The company completed a $75 million public offering, extending its cash runway into 2028, with $104.0 million in cash and investments as of September 30, 2025[2][13]. Clinical Development - CRB-701 demonstrated an objective response rate (ORR) of 47.6% in head and neck squamous cell carcinoma (HNSCC) and 37.5% in cervical cancer at a 3.6 mg/kg dose[6][7]. - The company plans to initiate a Phase 2/3 registrational study for CRB-701 by mid-2026 and has received Fast Track designations from the FDA for HNSCC and metastatic cervical cancer[8]. - CRB-913, an oral small molecule for obesity treatment, is expected to complete its single ascending dose and multiple ascending dose studies and initiate a Phase 1b study in Q4 2025[16]. Adverse Events - The most common treatment-emergent adverse events for CRB-701 included fatigue (21.6%), alopecia (24.0%), and keratitis (32.3%) with no grade 4 or 5 treatment-related adverse events reported[7][15].